We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Back to the science:
CD123 CAR-T was previously reported as UPenn's gold standard; here's what happened
https://ashpublications.org/blood/article/142/Supplement%201/217/503095/Cytokine-Release-Syndrome-Results-in-Reduced-AML
Note - one of the authors is Noelle Frey - who will now be the Principal Investigator for HEMO CAR-T Phase I at UPenn.
So - HEMO CAR-T now on pole position for the race to AML solution?
Blue finish by a maggots eyelash in very thin trading
1.615
Have a superb weekend all invested & lets see what next week brings
Hemo are clinical with cash in the bank & CBR & CDX cooking .
Afternoon all invested
Stagnant in thin volume awaiting updates .
3.3 million
To note -
Stock on loan / shorts
4.2 million -
Dropped 600 k yesterday- short closed
Cost to borrow- 15
Irrespective of daily market shenanigans,
Hemos science cogs keep turning & the stock will re rate when clinical news flows imo .
At current levels investors nibble fingers & use dry powder .
Recent Rns & article on Hemo very positive for the future.
Yeah I wondered that after posting, but thought it would have been done earlier in the week. You could be right though, makes sense
Those two look like a bed and isa . The second was at a higher price . Bid and offer were unchanged after and shortly after 300k appeared on the bid at 1.58
If the placing price is 2p, I ask the question would these guys sell at 1.2p or even below 1p?.........................Probably...........Extraordinary. Sometimes it takes time, but the SP always returns back to the placing price, EVENTUALLY.
12-Apr-24 08:13:37 1.553 1,000,000 Sell* 1.55 1.648 15.53k
12-Apr-24 08:13:26 1.55 1,000,000 Sell* 1.55 1.648 15.50k
Mr problem with MrI is that he can't make his mind up at all. I've never come across someone so erratic. If I was a new poster, on some days I'd think he's clearly pumping the stock here and is heavily invested. The next day, after a 0.1% drop, he seems like someone who has opened a short and is desperate to spread FUD. You can't change your beliefs and convictions in a stock/company on a daily basis. Yes there may be fluctuations from time to time based on certain events, but the guy seems to change like the wind.
OJ
What the fk are you talking about SS? What is India calling exactly? We can all see the stock has a low mcap compared to peers - we dont need him bleating about HEMO and Vlad everyday. Are you now suggesting he has some really deep insight - shall we follow the moan?
Is funding not secured to embark on Ph 1 trials? if you dont believe that why remain invested - just to fkn moan day in day out? and what is this truth that is being supressed
No one minds when posters are making up ridiculously positive statements but you are quite happy to have a pop at Mr I who is just calling it as it is. It's a public forum. If you don't agree /like his posts then filter him or don't read them. However, maybe it's more a case of wanting the truth suppressed.
There was that brief quieter (possibly confusing) period when the MrsI ID popped up...but yes, agree it's been otherwise pretty much constant.
Think my point was more why do you think anyone wants to hear you spouting your habitual frustration yet again? All are aware of your observations and will doubtless have considered some of them. But please stop it now.
Sure HT i will do whatever you want ... 14m shares being sold ...
Mrindia..you have moaned constantly for 4 years. At the beginning of the year you sold a huge chunk over 5m, and then it appears you bought them back despite your mates from the local chemist selling up and you not trusting Vlad....are you stupid or psychotic, I really cannot understand why you would but again...please do us all a favour, sell your shares and do one.
I guess because over time I have become a realist and recognised the pumps that came out of vlads mouth were just to raise money and nothing more. he has shafted many LTHs on here and gloats.
If he was really trying to help investors he would buy some shares himself out of the £400k salary he gets and raise a TR1 ... that would provide confidence to the market
They believed in the science but don't see any returns on this stock for 6 - 12 months and that is outside their investment horizon. That's their choice of course
MrI - why aren't you yet as tired of playing this broken record as some of us are of hearing you repeat it again and again and again and .... so on
Nothing is stopping these companies getting investment from the U.S.
Vlad never promised anything.
I guess your Pharma mates didn’t think much of the science / long term prospects. Seems they did a big u turn as well
EXPECTED to start not will in 2023
1) My pharma mates have sold out months ago. Once the shorters started killing the price, they sold out at 4p. I didn't stupidly
2) Vlad stated in his RNS from last year that trials would begin in 2023 ... how can he state that and this is now taking months etc? He then stated 2 months ago trials to begin in a few months. Again load of .... Trust is low in what he says and thats the problem
No one is rushing to invest here. Everytime there is a buy it is matched with a bigger sell and this price is being suppressed and could stay here for months sadly.
I have bitten the bullet and took a loss on half my holding. Something just doesnt add up here. Hope i am wrong, still a lot to lose/gain.. but feel better with a wedge off the table
Yet another UK listed company considers delisting and moving to US because UK investment just doesn't exist.
When will the authorities and institutions wake up and recognise that we are so far behind the investment curve in the UK in terms of new dynamicearly stage tech and pharma companies ?
India you say everyone is just 'speculating in trying to ramp or deramp the price' and then say it is dead as a dodo - you never seem to notice the hypocrisy in most of what you post. You never got back about your 3 big cheese pharma mates who are invested here? And would you mind pinpointing exactly what things Vlad promised?
This is dead as a dodo until we get some update on all the things vlad promised us as always !!!
To be honest I am not really sure about the 30%. being pedantic you cant divide 100 by 3 and get 30%. Does that mean safe in all 3 (or at least manageable side effects) with 1 showing signs of efficacy would equal success? That is kind of how I am reading it. Also the definition of success is important because we don't know the end points of the study -n of 3 is normally the minimum from a statistical point of view that you would select for very early stage feasibility it may not be the number of patients required to meet the clinical protocol end point. So my take is that the n-3 could provide initial proof of concept in humans which if successful (1 out of 3 showing efficacy) may be enough to access the non-dilutive funds mentioned to complete the phase1/2a study in a total of 18 AML patients. At that point the efficacy in patient population would be further understood and if Hemo CAR-T does show signs of efficacy then it would significantly de-risk the program and open doors to the big numbers that were mentioned in the article that pharma companies will pay for CAR-T products in the oncology space.
Goldwater - whats being made up and by who?